Zeleris

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
30-05-2017
Ciri produk Ciri produk (SPC)
30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
30-05-2017

Bahan aktif:

florfenicol, meloxicam

Boleh didapati daripada:

CEVA Santé Animale

Kod ATC:

QJ01BA99

INN (Nama Antarabangsa):

florfenicol, meloxicam

Kumpulan terapeutik:

Cattle

Kawasan terapeutik:

Amphenicols, combinations, Antibacterials for systemic use

Tanda-tanda terapeutik:

For therapeutic treatment of bovine respiratory disease (BRD) associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni susceptible to florfenicol.

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-05-15

Risalah maklumat

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET
ZELERIS 400 MG/ML + 5 MG/ML
SOLUTION FOR INJECTION FOR CATTLE
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
FRANCE
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
florfenicol / meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
1 ml contains 400 mg of florfenicol and 5 mg of meloxicam.
Clear yellow solution.
4.
INDICATION
For therapeutic treatment and of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
5.
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
6.
ADVERSE REACTIONS
Injection site reactions (mostly swelling, induration, heat and pain)
were very commonly observed
after subcutaneous administration of the product. These effects were
transitory and usually resolved
without any treatment within 5 to 15 days, but could persist up to 49
days.
During injection of this product animals may exhibit signs of moderate
pain, manifested as movement
of the head or neck.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals
treated)
- rare (more than 1 but less than 10 animals in 10,000 animals
treated)
- very rare (less than 1 a
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Florfenicol
400 mg
Meloxicam
5 mg.
EXCIPIENTS:
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For therapeutic treatment of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
4.3
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Whenever possible, the veterinary medicinal product should only be
used based on susceptibility
testing. Official, national and regional antimicrobial policies should
be taken into account when the
veterinary medicinal product is used.
Avoid use in severely dehydrated, hypovolaemic or hypotensive animals,
as there may be a potential
risk of renal toxicity. In the absence of safety data it is not
recommended to use the product in calves
less than 4 weeks old.
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
The product is slightly irritant to the eye. Rinse any splashes from
eyes immediately with plenty of
water.
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or
the label to the physician.
People with known hypersensitivity to florfenicol, meloxicam or to any
of th
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 30-05-2017
Ciri produk Ciri produk Bulgaria 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 30-05-2017
Risalah maklumat Risalah maklumat Sepanyol 30-05-2017
Ciri produk Ciri produk Sepanyol 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 30-05-2017
Risalah maklumat Risalah maklumat Czech 30-05-2017
Ciri produk Ciri produk Czech 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Czech 30-05-2017
Risalah maklumat Risalah maklumat Denmark 30-05-2017
Ciri produk Ciri produk Denmark 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 30-05-2017
Risalah maklumat Risalah maklumat Jerman 30-05-2017
Ciri produk Ciri produk Jerman 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 30-05-2017
Risalah maklumat Risalah maklumat Estonia 30-05-2017
Ciri produk Ciri produk Estonia 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 30-05-2017
Risalah maklumat Risalah maklumat Greek 30-05-2017
Ciri produk Ciri produk Greek 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Greek 30-05-2017
Risalah maklumat Risalah maklumat Perancis 30-05-2017
Ciri produk Ciri produk Perancis 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 30-05-2017
Risalah maklumat Risalah maklumat Itali 30-05-2017
Ciri produk Ciri produk Itali 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Itali 30-05-2017
Risalah maklumat Risalah maklumat Latvia 30-05-2017
Ciri produk Ciri produk Latvia 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 30-05-2017
Risalah maklumat Risalah maklumat Lithuania 30-05-2017
Ciri produk Ciri produk Lithuania 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 30-05-2017
Risalah maklumat Risalah maklumat Hungary 30-05-2017
Ciri produk Ciri produk Hungary 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 30-05-2017
Risalah maklumat Risalah maklumat Malta 30-05-2017
Ciri produk Ciri produk Malta 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Malta 30-05-2017
Risalah maklumat Risalah maklumat Belanda 30-05-2017
Ciri produk Ciri produk Belanda 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 30-05-2017
Risalah maklumat Risalah maklumat Poland 30-05-2017
Ciri produk Ciri produk Poland 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Poland 30-05-2017
Risalah maklumat Risalah maklumat Portugis 30-05-2017
Ciri produk Ciri produk Portugis 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 30-05-2017
Risalah maklumat Risalah maklumat Romania 30-05-2017
Ciri produk Ciri produk Romania 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Romania 30-05-2017
Risalah maklumat Risalah maklumat Slovak 30-05-2017
Ciri produk Ciri produk Slovak 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 30-05-2017
Risalah maklumat Risalah maklumat Slovenia 30-05-2017
Ciri produk Ciri produk Slovenia 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 30-05-2017
Risalah maklumat Risalah maklumat Finland 30-05-2017
Ciri produk Ciri produk Finland 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Finland 30-05-2017
Risalah maklumat Risalah maklumat Sweden 30-05-2017
Ciri produk Ciri produk Sweden 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 30-05-2017
Risalah maklumat Risalah maklumat Norway 30-05-2017
Ciri produk Ciri produk Norway 30-05-2017
Risalah maklumat Risalah maklumat Iceland 30-05-2017
Ciri produk Ciri produk Iceland 30-05-2017
Risalah maklumat Risalah maklumat Croat 30-05-2017
Ciri produk Ciri produk Croat 30-05-2017
Laporan Penilaian Awam Laporan Penilaian Awam Croat 30-05-2017

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen